This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Angelo, L. S. Articles by Kurzrock, R. Search for Related Content PubMed PubMed Citation Articles by Angelo, L. S. Articles by Kurzrock, R.

Vascular Endothelial Growth Factor and Its Relationship to Inflammatory Mediators

Authors' Affiliation: Phase I Program, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

Requests for reprints: Razelle Kurzrock, Division of Cancer Medicine, M. D. Anderson Cancer Center, Unit 422, P.O. Box 301402, Houston, TX 77030. Phone: 713-794-1226; Fax: 713-563-0566; E-mail: rkurzroc{at}mdanderson.org and Laura S. Angelo, Division of Cancer Medicine, M. D. Anderson Cancer Center. Phone: 713-817-2123; E-mail: langelo{at}alltel.net.

Abstract

Inflammation occurs in response to host injury or infection, as the result of an autoimmune disease, or in response to the development of a tumor. Although the immune system may be helpful in fighting the tumor, it may also fuel the tumorigenic process. In fact, recent data suggest a strong link between chronic inflammation, angiogenesis, and the development of cancer. For example, inflammation and scarring caused by recurring infections with Mycobacterium tuberculosis may be a cause for cancers of the lung. Inflammatory breast cancer exhibits increased angiogenesis and lymphangiogenesis and has a higher metastatic potential than noninflammatory breast cancer. Nonsteroidal anti-inflammatory drugs have been proposed as preventives for the development of colon carcinoma and ovarian cancer. Inhibition of nuclear factor-B contributes to the proposed mechanism of action. Inflammatory cytokines, including interleukin-6, serve as autocrine and paracrine growth factors for several cancers, and high levels of these cytokines may correlate with a poor prognosis and increased production of angiogenic factors. The state of the art of our understanding of this critical interaction is reviewed.

This article has been cited by other articles:

				B. P. Cheppudira, B. M. Girard, S. E. Malley, K. C. Schutz, V. May, and M. A. Vizzard Upregulation of vascular endothelial growth factor isoform VEGF-164 and receptors (VEGFR-2, Npn-1, and Npn-2) in rats with cyclophosphamide-induced cystitis Am J Physiol Renal Physiol, September 1, 2008; 295(3): F826 - F836. [Abstract] [Full Text] [PDF]

				G. M. Tse, A. W. H. Chan, K.-H. Yu, A. D. King, K.-T. Wong, G. G. Chen, R. K. Y. Tsang, and A. B. W. Chan Strong Immunohistochemical Expression of Vascular Endothelial Growth Factor Predicts Overall Survival in Head and Neck Squamous Cell Carcinoma Ann. Surg. Oncol., December 1, 2007; 14(12): 3558 - 3565. [Abstract] [Full Text] [PDF]